Basal cell carcinoma treated with interferon
| Autor: | N Djaković, Ikić D, I Kosutić, Ivo Padovan, Nedim Pipić, Knezević M, Mladen Belicza, Rodé B |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Adult
Male medicine.medical_specialty Pathology Skin Neoplasms medicine.medical_treatment Biopsy Alpha interferon Dermatology Injections Intralesional Gastroenterology Lesion Interferon Internal medicine medicine Humans Basal cell carcinoma Interferon alfa Aged Aged 80 and over Chemotherapy medicine.diagnostic_test business.industry Cancer Interferon-alpha Middle Aged medicine.disease Recombinant Proteins Carcinoma Basal Cell Interferon Type I Female medicine.symptom Facial Neoplasms business medicine.drug |
| Zdroj: | International journal of dermatology. 30(10) |
| ISSN: | 0011-9059 |
| Popis: | Human natural leukocytic interferon (HNLI) and recombinant interferon (rIFN) alpha 2c can be used in the therapy of basal cell carcinoma. Seventy-two patients were treated for 3 to 6 weeks with a single dose of 400,000 to 1,200,000 units (HNLI) and 2,000,000 to 5,000,000 units (rIFN alpha 2c). According to histopathologic and clinical findings, 52 patients were cured, and cancer cells were not found in the biopsy material taken after HNLI treatment for the second biopsy. In nine of 72 patients the cancer lesion was reduced 25% to 90%. In 11 patients it was not reduced or was reduced less than 25%. With rIFN alpha 2c therapy given five times per week for 4 weeks, histopathologic and clinical findings showed that five patients out of 12 were cured, and cancer cells were not found in the biopsy material taken after treatment. In seven patients out of 12 the cancer lesion was reduced 25% to 90%. Both types of interferons are effective in the treatment of basal cell carcinoma. Side effects were mild. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text